ADHD and Comorbidities – Management Principles
This review describes the common ADHD comorbidities and how their symptoms overlap with ADHD [Canadian ADHD Practice Guidelines]
If a patient is suspected of having ADHD, then during a medical review, the clinician should determine whether other medical and psychiatric disorders could mimic the symptoms of ADHD.
In some cases, ADHD may co-exist with another psychiatric comorbidity that influences the diagnosis and management.
You can go to the following links for a refresher on ADHD:
Pringsheim, T., Hirsch, L., Gardner, D., & Gorman, D. A. (2015). The pharmacological management of oppositional behaviour, conduct problems, and aggression in children and adolescents with attention-deficit hyperactivity disorder, oppositional defiant disorder, and conduct disorder: a systematic review and meta-analysis. Part 1: psychostimulants, alpha-2 agonists, and atomoxetine. Canadian journal of psychiatry. Revue canadienne de psychiatrie, 60(2), 42–51.
Crunelle, C. L., van den Brink, W., Moggi, F., Konstenius, M., Franck, J., Levin, F. R., … & Matthys, F. (2018). International consensus statement on screening, diagnosis and treatment of substance use disorder patients with comorbid attention deficit/hyperactivity disorder. European addiction research, 24(1), 43-51.
Levin, F. R., Mariani, J. J., Specker, S., Mooney, M., Mahony, A., Brooks, D. J., Babb, D., Bai, Y., Eberly, L. E., Nunes, E. V., & Grabowski, J. (2015). Extended-Release Mixed Amphetamine Salts vs Placebo for Comorbid Adult Attention-Deficit/Hyperactivity Disorder and Cocaine Use Disorder: A Randomized Clinical Trial. JAMA psychiatry, 72(6), 593–602.
Konstenius, M., Jayaram-Lindström, N., Guterstam, J., Beck, O., Philips, B., & Franck, J. (2014). Methylphenidate for attention deficit hyperactivity disorder and drug relapse in criminal offenders with substance dependence: a 24-week randomized placebo-controlled trial. Addiction (Abingdon, England), 109(3), 440–449.
McIntyre RS, Alsuwaidan M, Soczynska JK, Szpindel I, Bilkey TS, Almagor D, Woldeyohannes HO, Powell AM, Cha DS, Gallaugher LA, Kennedy SH. The effect of lisdexamfetamine dimesylate on body weight, metabolic parameters, and attention deficit hyperactivity disorder symptomatology in adults with bipolar I/II disorder. Hum Psychopharmacol. 2013 Sep;28(5):421-7.